Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tonix Pharma ( (TNXP) ) has provided an update.
Tonix Pharmaceuticals announced plans to initiate a Phase 2 trial of its TNX-102 SL product candidate for major depressive disorder in 2026, and an adaptive Phase 2/3 study of TNX-4800 for the seasonal prevention of Lyme disease in 2027. These developments are part of the company’s strategic efforts to expand its clinical pipeline and strengthen its position in the pharmaceutical market.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall score is driven by strong corporate events, particularly the FDA approval of Tonmya, which significantly boosts its market potential. However, challenges in profitability and valuation weigh down the score. Mixed technical indicators suggest cautious optimism.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development of innovative therapies for central nervous system disorders and infectious diseases. The company is known for its product candidates such as TNX-102 SL for fibromyalgia and TNX-4800 for Lyme disease prevention.
Average Trading Volume: 1,513,257
Technical Sentiment Signal: Strong Sell
Current Market Cap: $212.3M
Find detailed analytics on TNXP stock on TipRanks’ Stock Analysis page.